Phase 3 N=51 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Eosinophilic Esophagitis · Gastroesophageal Reflux Disease · EE
Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=572 Reflux Esophagitis Phase III Study (Initial Treatment)
Reflux Esophagitis
Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…
Phase 3 N=564 Reflux Esophagitis Phase III Study (Maintenance Treatment)
Reflux Esophagitis
Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants
N/A N=43 Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease
Gastroesophageal Reflux · Laryngopharyngeal Reflux
Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale
N/A N=42 Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants Who Responded — 7; 4 participants
N/A N=95 Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device
Laryngopharyngeal Reflux
Primary: Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks — -54.3 Per Cent Change — p=<0.05
N/A N=75 Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease
Gastro-esophageal Reflux Disease
Primary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change
N/A N=374 The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department
Gastroesophageal Reflux
Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants
Phase 3 N=337 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
Refractory Reflux Esophagitis
Primary: Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N) — 58.8; 78.4; 77.0 Percentage of…
Phase 3 N=26 A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
Non-erosive Gastroesophageal Reflux Disease
Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…
Phase 3 N=80 Gastroesophageal Reflux Treatment in Scleroderma
Gastroesophageal Reflux Disease · Systemic Sclerosis · Scleroderma
Primary: Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS) — 17.9; 17.2 VAS (100)
Phase 2 N=42 Topical Steroid Treatment for Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74
Phase 2 N=17 Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations
Cystic Fibrosis
Primary: Time to First Pulmonary Exacerbation — NA; NA Weeks
Phase 3 N=554 Esomeprazole (NEXIUM) vs. Surgery
Gastroesophageal Reflux
Primary: Number of Participants With Treatment Failure at 5 Years — 33; 19 participants
N/A N=58 Treatment of IPF With Laparoscopic Anti-Reflux Surgery
Idiopathic Pulmonary Fibrosis · Gastroesophageal Reflux
Primary: Forced Vital Capacity (FVC) — -0.13; -0.05 liters
Phase 4 N=305 Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
Non Erosive Reflux Disease · Chronic Gastritis
Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants
N/A N=30 Mucosal Impedance and Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms
N/A N=68 Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD
Gastroesophageal Reflux Disease (GERD)
Primary: The Number of Reflux in GERD Patients — 33.6; 42.8; 81.0; 53.1 episodes — p=0.002
Phase 4 N=276 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
Gastroesophageal Reflux Disease
Primary: Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study. — 34.3; 10.4 Percentage of participants
Phase 3 N=287 Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
Refractory Reflux Esophagitis
Primary: Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles…
N/A N=50 Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis
Suspected Eosinophilic Esophagitis
Primary: Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) — 69; 79 Percent Change
N/A N=47 Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease
GERD · Larynx Disease
Primary: Decrease in pH From Baseline to <4 — 1.1; 3.2; 3.8 distal esophagus total % time pH <4 — p=.05
Phase 4 N=3,029 Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
GERD
Primary: Efficacy of Three Strategies of Long-term Treatment — 10.6; 7.8; 43 Percentage of participants with failure
N/A N=1,045 Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders
Sleep Disorders · Non-Erosive Reflux Disease · Gastroesophageal Reflux Disease
Primary: Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours (Diaries) — 2.94; 2.62; 2.28; 2.03 Units on a scale
Phase 3 N=402 Study of Acid Reflux in Asthma
Asthma · Lung Diseases · Lung Diseases, Obstructive
Primary: Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion — 2.3; 2.5 events per person…
Phase 4 N=337 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
Gastroesophageal Reflux Disease
Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms
N/A N=63 Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy
GERD
Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes
N/A N=26 Outcomes of Esophageal Self Dilation for Benign Refractory Esophageal Stricture Management
Esophageal Dilation · Refractory Benign Esophageal Stricture
Primary: Number of Endoscopic Interventions — 12; 11; 12; 7 endoscopies
Phase 4 N=40 The Utility of Nexium in Chronic Cough and Reflux Disease
Cough · GERD
Primary: Change in Cough-Specific Quality of Life Questionnaire — 9.8; 5.8 participants
Phase 3 N=366 A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors
GERD
Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…